Carregant...
Defining and understanding adaptive resistance in cancer immunotherapy
Despite the unprecedented tumor regression and long-term survival benefit observed with anti-Programmed Death (PD) (anti-PD-1 or anti-B7-homolog 1 (B7-H1)) therapy in patients with advanced cancers, a large portion of patients do not benefit from such treatment and a fraction of responders relapse....
Guardat en:
| Publicat a: | Trends Immunol |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6066429/ https://ncbi.nlm.nih.gov/pubmed/29802087 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.it.2018.05.001 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|